Uncategorized

Using versus selling lucrative PRVs: Moderna’s cautionary tale

Using versus selling lucrative PRVs: Moderna’s cautionary tale

Published

5 days ago

on

As the prices paid for priority review vouchers (PRVs) have crept up over the past year — the last two have sold for at least $200 million each — companies now have to make difficult decisions on …​ ​Read More

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version